A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor
Status:
Terminated
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and
Flt3. Phase I study has shown that the toxicity is manageable.
The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in
patients with advanced or metastatic Gastroenteropancreatic Neuroendocrine Tumor.
Phase:
Phase 2
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences